Remove Chemotherapy Remove Events Remove Immunization
article thumbnail

Perioperative pembrolizumab improves outcomes in early-stage NSCLC

Hospital Pharmacy Europe

A perioperative approach that includes both neoadjuvant and adjuvant immune checkpoint inhibition with pembrolizumab significantly improves disease outcomes for patients with early-stage non-small-cell lung cancer (NSCLC), according to the findings of a trial by an international research group.

article thumbnail

EC approves Libtayo® for metastatic cervical cancer

European Pharmaceutical Review

s Libtayo ® (cemiplimab) for adults with recurrent or metastatic cervical cancer and disease progression while on or after platinum-based chemotherapy. “Libtayo ® was the first programmed cell death protein (PD)-1 inhibitor to demonstrate significant improvements in survival compared to chemotherapy in a Phase III trial.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Opdivo and chemotherapy combo increases survival in lung cancer patients

pharmaphorum

Lung cancer drug Opdivo administered with chemotherapy has been shown to boost survival rates in patients with resectable non-small cell lung cancer (NSCLC). The phase 3 CheckMate 816 study of Bristol-Myers Squibb’s Opdivo (nivolumab) revealed a significant improvement in event-free survival when the treatment regime is given before surgery.

article thumbnail

ESMO: TIL therapy improves on Yervoy in melanoma trial

pharmaphorum

With the results in hand, the developers of the therapy – from the Netherlands Cancer Institute and Norway’s National Center for Cancer Immune Therapy – say they now intend to file for regulatory approvals in Europe before the end of the year, without a commercial partner “to try to ensure that it remains affordable.”

article thumbnail

Trial highlights potential next-gen biologic for lung cancer

European Pharmaceutical Review

The biologic ZL-1310 is being investigated in an ongoing Phase Ia/Ib study in these patients who have had at least one platinum-based chemotherapy regimen. The monoclonal antibody therapy was reported to be well tolerated, with most treatment emergent adverse events (TEAE) Grade 1 or 2, according to the findings.

article thumbnail

Novartis extends Kaiku digital patient monitoring partnership

pharmaphorum

In May, a Phase 2 study started, comparing Kaiku’s electronic patient-reported outcome (ePRO) approach to evaluating immune-related adverse events to the standard model of care in cancer patients treated with checkpoint inhibitor drugs, with results due towards the end of 2023 or in early 2024.

article thumbnail

A history of blood cancer treatment

pharmaphorum

As we enter Blood Cancer Awareness month, a global event dedicated to spotlighting and supporting efforts to improve awareness, detection, and treatment of blood cancer, we take a look back in celebration of the achievements and breakthroughs that paved the way for today’s innovations. 1942 – Chemotherapy moves from trenches to treatment .